Browsing category:


On August 30, 2012 Ironwood Pharmaceuticals Inc. and Forest Laboratories Inc. gained U.S. regulatory approval of Linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C). The trade name for Linaclotide is Linzess. The National Institutes of Health estimates that roughly 63 million people are affected by chronic constipation, and about 15.3 million people[…]

Read More